Thought leadership from the sAÏmone team — exploring how AI-native intelligence is reshaping Medical Affairs strategy, evidence synthesis, and competitive analysis.
Rare disease conversations in Latin America need to move beyond awareness toward systemic solutions. Brazil, Chile, and Mexico have each built components of care architecture — but the region lacks a unified framework to connect these efforts and ensure equitable cross-border access.
What happens when semaglutide loses patent protection? Canada was first, but India provides the more revealing case study — immediate generic launches, a self-pay market, and no government GLP-1 reimbursement. Game-theoretic modelling forecasts how competitive dynamics unfold across four distinct market layers.
Two anti-amyloid therapies are now approved in the US — but most eligible patients never receive treatment. The bottleneck isn't drug efficacy. It's a systemic diagnosis-and-delivery failure across the entire patient pathway, from symptom recognition to infusion logistics.